Breaking News From ADA 2020


This page was last updated at 7:46 am PT June 16, 2020.

Editor’s Note: This article will be updated regularly with breaking news and announcements during the course of the ADA Scientific Sessions Conference. Check back often! Follow along on twitter at #ADA2020

Tuesday, June 16, 2020

  • New rapid-acting insulin Lyumjev from Lilly receives FDA approval for type 1 and type 2 diabetes. More information to come on the specific time to action, prescribing information indicates that it should be taken at meals or up to twenty minutes following meals, and is designed to manage after-meal spikes better than Humalog or similar insulins. It is not yet approved for use in insulin pumps or for children.

Monday, June 15 2020

  • Results from the Trends in Glycemic Control among Youth with Diabetes: The SEARCH for Diabetes in Youth Study revealed that despite the increased availability of diabetes technology, new therapies and more aggressive control targets, today’s young adults and youth have worse glycemic control than previous youth and young adult groups from 2002-2007. Data shows these new groups currently aren’t meeting A1C recommendations. Youth and young adults with type 1 diabetes had an average A1c with 8.7 percent, while those with type 2 diabetes had an estimated average A1c of 8.5 percent. “Given the evidence highlighting the benefits of tight glycemic control, this study reinforces the need for interventions that combine the use of diabetes technology with effective behavioral and social approaches to improve A1C levels,” said the study’s lead author Faisal Malik, MD, MSHS, assistant professor of pediatrics at the University of Washington School of Medicine, investigator at the Center for Child Heath, Behavior and Development at Seattle Children’s Research Institute, and a pediatric endocrinologist at Seattle Children’s Hospital.
  • Abbott announced that the FDA has approved the FreeStyle Libre 2 System—it is approved for adults and children 4 and up in the United States. The FreeStyle Libre 2 is a 14 day continuous glucose monitor (CGM) system that transmits data every minute and now includes customizable high and low alerts without the need to scan the device. The Abbott announcement says it will be “a third of the cost of other CGMs.”
  • One Drop unveiled new AI-powered predictions for blood glucose, A1C, blood pressure and weight up to six months in advance, as well as overnight hypoglycemia predictions For CGM Users. The company plans to roll these features out to users within the year.

Saturday, June 13 2020

Friday, June 12 2020

Thursday, June 11 2020

Click here for complete coverage of ADA 2020 from Beyond Type 1.